Literature DB >> 31704720

In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment.

Christina Adamichou1, Dionysis Nikolopoulos2, Irini Genitsaridi3, Alessandra Bortoluzzi4, Antonis Fanouriakis2, Emmanouil Papastefanakis1, Eleni Kalogiannaki1, Irini Gergianaki1, Prodromos Sidiropoulos1,5, Dimitrios T Boumpas2,6, George K Bertsias7,5.   

Abstract

OBJECTIVES: Classification criteria are biased towards classifying long-standing disease. We compared the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR)-2019, Systemic Lupus International Collaborating Clinics (SLICC)-2012 and ACR-1997 criteria in an early (median 48 months) systemic lupus erythematosus (SLE) cohort.
METHODS: Patients diagnosed with SLE (n=690) or control diseases (n=401). Sensitivity, specificity of the criteria and time-to-classification were calculated. Modified classification algorithms were derived from a random 80% and validated in the remaining 20% of the dataset running multiple iterations.
RESULTS: At last assessment, sensitivities of ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria were 85.7%, 91.3% and 88.6%, with specificities 93.0%, 93.8% and 97.3%, respectively. Both SLICC and EULAR/ACR enabled earlier classification. Only 76.7% of patients with SLE met all three criteria suggesting non-overlapping groups. Notably, unclassified patients had high prevalence of British Isles Lupus Assessment Group moderate/severe manifestations (43.3%-60%) and SLICC/ACR organ damage (30%-50%). At diagnosis, criteria missed 25.6%-30.5% of patients. Modification of EULAR/ACR and SLICC algorithms to include hypocomplementaemia and/or positive anti-phospholipid antibodies as alternative entry criterion, and/or allow classification with fewer clinical criteria from multiple organs, increased their sensitivity at diagnosis (median 82.0% and 86.2%) and overall (93.7% and 97.1%) with modest decreases in specificity. Importantly, patients who were still missed by the modified criteria had lower incidence of major organ involvement, use of immunosuppressive/biological therapies and organ damage.
CONCLUSIONS: The SLICC and EULAR/ACR are more sensitive than the ACR and the EULAR/ACR criteria have superior specificity in early SLE, although patients with significant disease can be missed. Combination and/or modification of the classification algorithms may enhance their sensitivity, allowing earlier classification and treatment of more patients with high disease burden. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  autoimmune diseases; outcomes research; systemic lupus erythematosus

Year:  2019        PMID: 31704720     DOI: 10.1136/annrheumdis-2019-216155

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  15 in total

Review 1.  Differentiating between UCTD and early-stage SLE: from definitions to clinical approach.

Authors:  Savino Sciascia; Dario Roccatello; Massimo Radin; Ioannis Parodis; Jinoos Yazdany; Guillermo Pons-Estel; Marta Mosca
Journal:  Nat Rev Rheumatol       Date:  2021-11-11       Impact factor: 20.543

2.  Evaluation of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in children and adults.

Authors:  Sang Cheng; Huihua Ding; Haiyan Xue; Lanfang Cao
Journal:  Clin Rheumatol       Date:  2022-07-19       Impact factor: 3.650

3.  Systemic lupus erythematosus as a genetic disease.

Authors:  Isaac T W Harley; Amr H Sawalha
Journal:  Clin Immunol       Date:  2022-02-09       Impact factor: 10.190

Review 4.  Tailored treatment strategies and future directions in systemic lupus erythematosus.

Authors:  Dionysis Nikolopoulos; Lampros Fotis; Ourania Gioti; Antonis Fanouriakis
Journal:  Rheumatol Int       Date:  2022-04-21       Impact factor: 3.580

Review 5.  Acute acalculous cholecystitis as the initial manifestation of systemic lupus erythematous: A case report.

Authors:  Jeonghun Lee; Young Joo Lee; Youngsun Kim
Journal:  Medicine (Baltimore)       Date:  2021-06-04       Impact factor: 1.817

Review 6.  A Contemporary Update on the Diagnosis of Systemic Lupus Erythematosus.

Authors:  Xin Huang; Qing Zhang; Huilin Zhang; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2022-01-22       Impact factor: 8.667

7.  Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease.

Authors:  Dionysis S Nikolopoulos; Myrto Kostopoulou; Dimitrios T Boumpas; Antonis Fanouriakis; Antigoni Pieta; Sofia Flouda; Katerina Chavatza; Aggelos Banos; John Boletis; Pelagia Katsimbri
Journal:  Lupus Sci Med       Date:  2020-06

8.  Evolving phenotype of systemic lupus erythematosus in Caucasians: low incidence of lupus nephritis, high burden of neuropsychiatric disease and increased rates of late-onset lupus in the 'Attikon' cohort.

Authors:  D Nikolopoulos; M Kostopoulou; A Pieta; T Karageorgas; D Tseronis; K Chavatza; S Flouda; P Rapsomaniki; A Banos; E Kremasmenou; V Tzavara; P Katsimbri; A Fanouriakis; D T Boumpas
Journal:  Lupus       Date:  2020-02-27       Impact factor: 2.911

Review 9.  Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus.

Authors:  Haitao Yu; Yasuo Nagafuchi; Keishi Fujio
Journal:  Biomolecules       Date:  2021-06-22

10.  Assessment of EULAR/ACR-2019, SLICC-2012 and ACR-1997 Classification Criteria in SLE with Longstanding Disease.

Authors:  Berta Magallares; David Lobo-Prat; Ivan Castellví; Patricia Moya; Ignasi Gich; Laura Martinez-Martinez; Hye Park; Ana Milena Millán; Ana Laiz; César Díaz-Torné; Susana Fernandez; Hèctor Corominas
Journal:  J Clin Med       Date:  2021-05-28       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.